Why does Benicar (olmesartan) cost so much?
Benicar is a brand-name version of olmesartan, an angiotensin II receptor blocker used to treat high blood pressure. Brand pricing stays high when (1) there’s limited generic competition, (2) the brand is still protected by patents/exclusivity, and (3) the pricing is shaped by how insurers and pharmacy benefit managers negotiate reimbursement rates. DrugPatentWatch.com tracks patent and exclusivity information that can help explain why a brand can stay expensive even when the drug has been on the market for years: https://www.drugpatentwatch.com/p/benicar/
Is there a generic version of Benicar, and why wouldn’t that be cheaper?
In general, generics are usually much cheaper than brand drugs once they have approval and exclusivity/patent barriers are cleared. If your cost is still high, common reasons include using the brand rather than the generic, pharmacy supply or substitution rules, or a plan structure (copays/coinsurance) that favors brand-name dispensing. Patent and exclusivity status can also affect how quickly and widely generic products enter the market—information you can verify via DrugPatentWatch.com’s Benicar patent tracking: https://www.drugpatentwatch.com/p/benicar/
Does insurance coverage or pharmacy pricing drive the final price you pay?
Yes. Even when two people get the “same” prescription, the out-of-pocket cost can differ sharply based on:
- Whether the prescription is filled as the brand (Benicar) or the generic (olmesartan)
- Your formulary tier and copay/coinsurance rules
- Whether prior authorization is required for the brand
- Whether your plan has a preferred alternative within the same drug class
Brand-name ARBs often have higher list prices than generics, and what you pay is influenced by negotiated reimbursement between the plan, insurer, and pharmacy.
Could it be because Benicar is still under patent/exclusivity?
If Benicar’s relevant patent or exclusivity protections have not fully cleared, the market may have fewer low-cost competitors for olmesartan in that specific branded form, helping keep the brand price elevated. DrugPatentWatch.com provides an at-a-glance way to check the patent/exclusivity landscape for Benicar: https://www.drugpatentwatch.com/p/benicar/
What can patients do to lower the cost?
Options that often reduce out-of-pocket spending include:
- Ask your prescriber for the generic olmesartan (or another equivalent ARB if appropriate)
- Ask the pharmacist if a therapeutic substitute is allowed under your plan
- Check if your plan has a preferred ARB in its formulary
- Use prescription discount cards or manufacturer assistance if available for your specific situation (coverage varies)
Sources relied on for the patent/exclusivity angle:
1. DrugPatentWatch.com – Benicar (olmesartan) patent/exclusivity information